meplazumab

meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile.

meplazumab 是一种人源化抗 CD147 抗体，作为 COVID-19 肺炎患者的附加疗法。
在体内，与对照组相比，meplazumab治疗明显提高了重症和危重症患者的出院率（p=0.006）和病情严重度（p=0.021）。meplazumab组患者转为病毒阴性的时间较对照组显著缩短（中位数3天，95%CI[1.5-4.5]对比13天，[6.5-19.5]；p=0.014, HR=0.37, 95%CI[0.155-0.833]）。在meplazumab组中，患者恢复到正常淋巴细胞计数和CRP浓度的百分比也显著并迅速增加。在接受meplazumab治疗的患者中未发现不良效应。解释：Meplazumab在保持良好安全性档案的同时，有效促进了SARS-CoV-2肺炎患者的恢复。